Alzamend Neuro
ALZN
11 hedge funds and large institutions have $351K invested in Alzamend Neuro in 2025 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
5,429% more capital invested
Capital invested by funds: $6.36K → $351K (+$345K)
400% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 1
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
57% more funds holding
Funds holding: 7 → 11 (+4)
4.43% more ownership
Funds ownership: 0.27% → 4.7% (+4.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$237K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$56.1K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$53.4K |
| 4 |
CA
Clearstead Advisors
Cleveland,
Ohio
|
+$26K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.05K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$10 |
| 2 |
AWM
Activest Wealth Management
Aventure,
Florida
|
-$5 |
ALZN Hedge Fund Activity: Q3 2025 in Review
11 of the 7,644 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q3 2025, worth a combined $351K — up 5,429% from $6.36K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ALZN positions and 1 closed out — a net gain of 4 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was DRW Securities, opening a new position worth an estimated $237K. The largest seller was BlackRock, cutting an estimated $10.
- 11 institutional investors held Alzamend Neuro (ALZN) as of Q3 2025, up from 7 in Q2 2025.
- Funds reported $351K of Alzamend Neuro stock for Q3 2025, up 5,429% quarter-over-quarter.
- 5 funds opened new Alzamend Neuro positions in Q3 2025 and 1 closed out, a net change of +4 holders.
- The largest Alzamend Neuro buyer in Q3 2025 was DRW Securities, an estimated $237K added.
- The largest Alzamend Neuro seller in Q3 2025 was BlackRock, an estimated $10 sold.
Based on aggregated 13F filings for Q3 2025.